This Article Full Text Full Text (PDF) All Versions of this Article: 93/2/470    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Valkenburg, O. Articles by Laven, J. S. E. Search for Related Content PubMed PubMed Citation Articles by Valkenburg, O. Articles by Laven, J. S. E. Related Collections Cardiovascular Endocrinology Female Endocrinology

A More Atherogenic Serum Lipoprotein Profile Is Present in Women with Polycystic Ovary Syndrome: A Case-Control Study

Department of Gynecology, Divisions of Reproductive Medicine (O.V., J.S.E.L.) and Obstetrics and Prenatal Medicine (R.P.M.S-T., H.P.M.S.), and Departments of Epidemiology and Biostatistics (R.P.M.S.-T.), Clinical Genetics (R.P.M.S.-T.), and Pediatrics/Division of Pediatric Cardiology (R.P.M.S.-T.), Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands; Laboratory of Experimental Vascular Medicine (G.M.D.-T.), Academic Medical Center, 1100 DD Amsterdam, The Netherlands; and Departments of Reproductive Medicine (B.C.J.M.F.) and Internal Medicine (E.H.W.), University Medical Center, 85500 3508 GA Utrecht, The Netherlands

Address all correspondence and requests for reprints to: O. Valkenburg, M.D., Division of Reproductive Medicine, Department of Gynecology and Obstetrics, Room HS 508, Erasmus Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. E-mail: o.valkenburg{at}erasmusmc.nl.

Context: Polycystic ovary syndrome (PCOS) is associated with a higher frequency of cardiovascular risk factors. Apolipoprotein (apo) A-I and apoB are potent markers for cardiovascular risk. Data on apo levels in women with PCOS are scarce and contradictory.

Objective: Our objective was to identify changes in lipid metabolism in women with PCOS, and the relative impact of obesity, insulin resistance, and hyperandrogenism on lipid parameters.

Design: This was a case-control study.

Setting: The study was performed at a single referral center.

Subjects: PCOS was diagnosed according to the 2003 Rotterdam criteria. Healthy mothers with regular menstrual cycles served as controls.

Main Outcome Parameters: Fasting insulin, triglycerides (TGs), cholesterol, high-density lipoprotein (HDL)-cholesterol, apoA-I, and apoB were determined. Low-density lipoprotein (LDL)-cholesterol was calculated using the Friedewald formula.

Results: We included 557 women with PCOS and 295 controls. After correction for age and body mass index, PCOS women had higher median levels of insulin (10.1 vs. 6.9 mU/liter), TGs (95 vs. 81 mg/dl), cholesterol (196 vs. 178 mg/dl), and LDL-cholesterol (125 vs. 106 mg/dl) in combination with lower levels of HDL-cholesterol (46 vs. 55 mg/dl) and apoA-I (118 vs. 146 mg/dl) compared with controls (all P values 0.01). apoB levels were similar in cases and controls. Free androgen index, body mass index, SHBG, and estradiol were independent predictors of apoA-I levels in women with PCOS.

Conclusions: PCOS is associated with a more pronounced atherogenic lipid profile. Furthermore, obesity and hyperandrogenism contribute to an adverse lipid profile. Finally, PCOS seems to constitute an additional risk factor for an atherogenic lipid profile.

This article has been cited by other articles:

				R. L. Barbieri Update in Female Reproduction: A Life-Cycle Approach J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2439 - 2446. [Abstract] [Full Text] [PDF]